Replies to post #18302 on Biotech Values

[spartex]

<Events seem to be unfolding as predicted in #msg-8310781 (item #2).>

Dew, what about your #3 prediction. So you are saying that these plans for buildout are going to be moved to the backburner next?

3. DNDN will talk less often about its manufacturing buildout because these plans will be moved to the back burner.


The DNDN PR specifically says that "the realignment "best positions" the company as it prepares to commercialize Provegne, an advanced trial drug used to treat prostate cancer."

Time will tell which way #3 ends up going (unfolding) and whether Mitch is a straight shooter or not, eh?

Regards, Spartex